Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer

Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer

The Notch-signaling ligand DLL1 has emerged as an important player and promising therapeutic target in breast cancer (BC). DLL1-induced Notch activation promotes tumor cell proliferation, survival, migration, angiogenesis and BC stem cell maintenance. In BC, DLL1 overexpression is associated with po...

Full description

Bibliographic Details
Main Authors: Gabriela Silva, Joana Sales-Dias, Diogo Casal, Sara Alves, Giacomo Domenici, Clara Barreto, Carolina Matos, Ana R. Lemos, Ana T. Matias, Khrystyna Kucheryava, Andreia Ferreira, Maria Raquel Moita, Sofia Braga, Catarina Brito, M. Guadalupe Cabral, Cristina Casalou, Duarte C. Barral, Pedro M. F. Sousa, Paula A. Videira, Tiago M. Bandeiras, Ana Barbas
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
ER<sup>+</sup> breast cancer
Notch signaling
DLL1
monoclonal antibody
cell proliferation
angiogenesis
Online Access:https://www.mdpi.com/2072-6694/13/16/4074

Internet

https://www.mdpi.com/2072-6694/13/16/4074

Similar Items